Summit Therapeutics (SMMT) EBIAT (2022 - 2025)
Summit Therapeutics (SMMT) has disclosed EBIAT for 4 consecutive years, with -$219.2 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT fell 258.11% year-over-year to -$219.2 million, compared with a TTM value of -$1.1 billion through Dec 2025, down 387.81%, and an annual FY2025 reading of -$1.1 billion, down 387.81% over the prior year.
- EBIAT was -$219.2 million for Q4 2025 at Summit Therapeutics, up from -$231.8 million in the prior quarter.
- Across five years, EBIAT topped out at -$14.7 million in Q2 2023 and bottomed at -$565.7 million in Q2 2025.
- Average EBIAT over 4 years is -$139.4 million, with a median of -$58.3 million recorded in 2024.
- The sharpest move saw EBIAT skyrocketed 91.98% in 2024, then plummeted 836.84% in 2025.
- Year by year, EBIAT stood at -$19.2 million in 2022, then plummeted by 90.17% to -$36.6 million in 2023, then plummeted by 67.37% to -$61.2 million in 2024, then crashed by 258.11% to -$219.2 million in 2025.
- Business Quant data shows EBIAT for SMMT at -$219.2 million in Q4 2025, -$231.8 million in Q3 2025, and -$565.7 million in Q2 2025.